HC Wainwright set a $12.00 price objective on Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other analysts also recently issued reports on the company. BidaskClub raised Pieris Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Monday, February 5th. ValuEngine raised Pieris Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, February 2nd. Finally, William Blair began coverage on Pieris Pharmaceuticals in a research note on Wednesday, January 17th. They issued an outperform rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Pieris Pharmaceuticals has an average rating of Buy and an average price target of $10.00.

Shares of Pieris Pharmaceuticals (PIRS) opened at $8.59 on Friday. Pieris Pharmaceuticals has a 12 month low of $1.88 and a 12 month high of $8.79. The stock has a market capitalization of $320.28, a P/E ratio of -11.61 and a beta of 1.57.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The business had revenue of $3.93 million for the quarter, compared to the consensus estimate of $1.52 million. The company’s revenue was up 400.3% on a year-over-year basis. equities analysts predict that Pieris Pharmaceuticals will post -0.62 earnings per share for the current year.

In other news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total transaction of $12,565,707.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.05% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PIRS. State Street Corp bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $2,377,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Pieris Pharmaceuticals during the 4th quarter valued at approximately $3,370,000. Northern Trust Corp bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $1,625,000. TIAA CREF Investment Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $649,000. Finally, Vanguard Group Inc. bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at approximately $526,000. 50.78% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2018/02/10/pieris-pharmaceuticals-pirs-pt-set-at-12-00-by-hc-wainwright.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.